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Background: Evidence suggests that the use of anti-inflammatory agents may improve 
depressive symptoms in patients with bipolar affective disorder. However, there are few well-
designed clinical trials demonstrating the efficacy of these newer treatment strategies.
Patients and methods: This is a multicenter, 3-month, randomized, placebo-controlled, 
double-blind, factorial design trial of minocycline and/or celecoxib added to TAU for the 
treatment of depressive symptoms in patients experiencing a DSM-5 bipolar I or II disorder 
and a current major depressive episode. A total of 240 participants will undergo screening and 
randomization followed by four assessment visits. The primary outcome measure will be mean 
change from baseline to week 12 on the Hamilton Depression Scale scores. Clinical assessments 
using the Clinical Global Impression scale, Patient Health Questionnaire-9, and the Generalized 
Anxiety Disorder 7-item scale will be carried out at every visit as secondary outcomes. Side-
effect checklists will be used to monitor the adverse events at each visit. Complete blood count 
and plasma C-reactive protein will be measured at baseline and at the end of the treatment. 
Minocycline will be started at 100 mg once daily and increased to 200 mg at 2 weeks. Celecoxib 
will be started at 200 mg once daily and increased to 400 mg at 2 weeks.
Discussion: Anti-inflammatory agents have been shown to be potentially efficacious in the 
treatment of depressive symptoms. The aim of this study is to determine whether the addition of 
minocycline and/or celecoxib to TAU improves depressive symptoms in patients with bipolar 
affective disorder.
Keywords: bipolar disorder, depression, inflammation, anti-inflammatory, minocycline, 
celecoxib
Background
Bipolar disorder affects ∼2% of the population and is associated with significant 
morbidity and mortality.1 It is in many cases a chronic and debilitating illness, often 
with poor recovery between episodes.2,3 The current mainstay of treatment is mood-
stabilizing medication often augmented with antipsychotics. However, there is often 
a suboptimal response to these treatments with poor tolerance of the drugs due to 
adverse effects.4–6 The depressive phase in both bipolar I and II remains a significant 
treatment challenge, particularly given the uncertainty surrounding the efficacy and 
use of antidepressants and the associated risk of manic switch with these drugs.4 It has 
been reported that after initial onset, patients with bipolar disorder have residual 
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depressive symptoms for about a third of their lives.7 There 
is a clear need to search for new treatment approaches for 
these patients. 
Inflammatory processes are believed to play a role in 
psychiatric conditions including depression and bipolar 
disorder. This hypothesis is based on findings from recent 
studies in both the preclinical and clinical phases. Multiple 
reviews have clearly demonstrated that bipolar disorder 
is associated with abnormal levels of circulating pro- and 
anti-inflammatory immune biomarkers in the affected 
patients.8,9 Studies have also revealed elevated levels of 
pro-inflammatory cytokines, TNF-α and IL-4, and their 
receptors sTNFR1 and sIL-2R in patients with bipolar 
disorder.8 However, a recent meta-analysis has indicated that 
the levels of inflammatory biomarkers in bipolar disorder 
may be dependent on the mood episode (ie, manic, depressed, 
and euthymic).10 A study in 2015 compared the inflamma-
tory status of patients with bipolar I disorder with healthy 
controls and found that
[...] those with either mania or depression had sig-
nificantly elevated levels of TNF-α, its soluble recep-
tors (sTNFR1/sTNFR2), other macrophage-derived 
cytokines (interleukin 1β [IL-1β], IL-6, IL-10, and 
IL-18) in addition to IL-4, interferon-γ, monocyte 
chemotactic protein-1, fibroblast growth factor β  
and vascular endothelial growth factor.11
The link between inflammatory medical illnesses and 
higher rates of psychiatric comorbidities (especially major 
depressive disorder) also strengthens the inflammatory 
hypothesis for mood disorder. For instance, in patients who 
suffer from both Crohn’s disease and depression, exacerba-
tions of physical illness tend to occur at the same time as 
depressive episodes.12 Furthermore, patients treated with 
cytokines for various physical health conditions are at an 
increased risk of developing depression; up to 45% of patients 
experience depressive symptoms following treatment with 
cytokine IFN-α.13,14 Bipolar disorder has also been proposed 
as a multisystemic inflammatory disease due to the significant 
somatic comorbidity associated with it.15
Current evidence suggests that adjunctive anti- 
inflammatory medication may be effective in the treatment 
of affective disorders.16–19 Minocycline is a tetracycline 
antibiotic that has good penetration through the blood–brain 
barrier and can affect multiple systems including the anti-
inflammatory, antioxidant, antiapoptotic, glutamatergic, 
and monoaminergic pathways. These pathways have all 
been implicated in the etiology of mood disorders. For this 
reason, minocycline has previously been proposed for the 
treatment of depressive symptoms and negative symptoms 
in schizophrenia.20,21 An open-label study of patients with 
psychotic unipolar depression found that minocycline 
augmentation of antidepressant treatment was effective in 
improving depressive symptoms and was well tolerated.22 
A recent double-blind RCT of minocycline used for mild-to-
moderate depression in patients diagnosed with HIV+ found 
that it was well tolerated and effective in reducing depressive 
symptoms after 6 weeks of treatment.23
Similarly, several clinical trials have shown promising 
results when investigating celecoxib for the treatment of 
depressive symptoms. A recent meta-analysis showed that 
using celecoxib as an add-on to antidepressant therapy led to 
a significant improvement in symptoms, as well as improving 
both response and remission in patients with major depressive 
disorder compared with placebo.19 There is currently only 
one clinical trial that has investigated the use of celecoxib 
in bipolar depression.24 This was an RCT of 28 participants 
with bipolar disorder experiencing a depressive or mixed 
episode. The authors found that
patients receiving celecoxib had lower HAM-D scores 
after one week of treatment compared to the patients 
receiving placebo, but this difference was not statistically 
significant,
and by the end of the 6-week trial, there was no difference in 
depression scores between patients receiving celecoxib and 
those receiving placebo.24 
In this factorial design, double-blind RCT, the safety and 
efficacy of minocycline and/or celecoxib will be determined 
as adjuncts to TAU in patients experiencing a depressive 
phase of bipolar I or II disorder. This study hypothesizes 
that augmentation with minocycline and/or celecoxib will 
improve depressive symptoms in participants, compared 
with TAU alone.
Objective
To investigate whether the addition of minocycline and/or 
celecoxib to TAU for 12 weeks in patients experiencing a 
depressive phase of bipolar disorder will lead to an improve-
ment in depressive symptoms compared with TAU.
Patients and methods
Study design
This is a multicenter, 12-week, randomized, double-blind, 
placebo-controlled, factorial designed trial of minocycline 
and/or celecoxib added to TAU for patients suffering from 
DSM-5 bipolar I or II disorder and a current major depres-
sive episode.
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The study will adopt a 2×2 factorial design, with 60 
completers in each arm, giving a total of 240 participants 
over the study period (Table 1). The study will be a four-
arm trial; one arm will receive minocycline with TAU; the 
second arm will receive celecoxib with TAU; the third arm 
will receive both minocycline and celecoxib with TAU; and 
the fourth arm will receive placebo with TAU.
Recruitment will occur at outpatient psychiatric clinics 
in Karachi, Lahore, and Rawalpindi, Pakistan. All partici-
pants will provide written informed consent after reading 
the information in English and/or Urdu. TAU will consist of 
medication including mood stabilizers, antipsychotics, and 
antidepressants (SSRIs, Tricyclics, MAOIs, and SNRIs), 
psychotherapy and other psychosocial interventions.
Trial status
This trial (Clinicaltrials.gov identifier NCT02703363) was 
registered in March 8, 2016, and is currently recruiting 
participants. The study completion date is estimated to be 
August 2018.
randomization
A restricted randomization (permuted block randomization) 
method will be used in which subjects are randomly allo-
cated to each block (n=60) to ensure that equal numbers 
of participants receive each drug/placebo combination. 
An off-site statistician, who will not be involved in clinical 
assessments, will determine randomization sequences. The 
statistician will assign the treatment code to the participant 
after the consenting phase.
Participants, their carers, referring psychiatrists, and the 
researchers carrying out assessments will be blind to the study 
drugs until completion. A single pharmacy at each center will 
be responsible for dispensing minocycline, celecoxib, and 
placebo in identical tablet form and matched for size, shape, 
and color. Study medication will be obtained from a local 
pharmaceutical company that will hold ISO certification.
Sample size
An effect size of 0.40 or higher is considered clinically 
significant as criteria for response in clinical trials of 
antidepressants.25 It is also assumed that there is no inter-
action between the two interventions and thus the study is 
powered to measure only for the main effects. The sample 
size is adjusted for 20% attrition rate due to loss to follow-up 
and/or dropout. With these assumptions, a sample size of 
262 would give 90% power to detect an SMD of 0.45 at 5% 
level of significance. 
Sample size was calculated based on a group SMD of 
0.45 SD on the HAM-D scores, for either minocycline or 
celecoxib. This is a moderate size effect and is the minimal 
that would be of clinical interest.
In addition, it is possible to improve statistical precision by 
adjusting for baseline HAM-D levels in the primary analysis. 
If a correlation between baseline and treatment outcome of 
0.4 is assumed conservatively, a simple design effect can 
be calculated according to the formula 1–ρ2,26 giving a sample 
size deflation of 0.84 and a total sample size of 222.
Ethics approval
The ethics committee of KMDC in Karachi, Pakistan, has 
provided IRB approval for the study.
Inclusion criteria
1. Males or females aged 18–65 years
2. DSM-5 diagnosis of bipolar I or II disorder and current 
major depressive disorder
3. Experiencing current depressive symptoms for at least 
4 weeks (HAM-D-17 score $18)
4. Willing and able to provide informed consent
5. Taking current medication for at least 4 weeks prior to 
baseline assessment
6. Able to take medication in tablet form
7. If female and of child-bearing age, agrees to use contra-
ception and consents to monthly pregnancy tests.
Exclusion criteria
1. Serious physical health condition (eg, HIV, renal, hepatic, 
cardiac, and serious dermatological disorders such as exfo-
liative dermatitis and systemic lupus erythematosus)
2. History of allergies/adverse effects to any of the tetracy-
clines or other anti-inflammatory medication
3. Current treatment with penicillin
4. Current use of anticoagulant medication
5. History of seizures
6. Current use of other antibiotics, other NSAIDs, acetazo-
lamide, or methotrexate
7. Change of psychiatric medications within the preceding 
4 weeks
8. History of substance misuse or dependence within the 
preceding 3 months according to DSM-5 criteria
9. Pregnant or breast-feeding
Table 1 2×2 factorial design table showing number of participants 
in each arm
Placebo Minocycline Total
Placebo 60 60 120
celecoxib 60 60 120
Total 120 120
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10. Diagnosis of primary psychotic disorder
11. High risk of suicide
12. Three or more concurrent manic/hypomanic symptoms.
The criteria for leaving the study are as follows: 1) at the 
participant’s request, 2) at the discretion of the responsible 
physician or trial investigator (eg, an adverse event and a 
poor compliance), and 3) pregnancy. 
Study procedure
recruitment
Initially, the research team will approach local clinical 
teams to inform them about the trial and provide them with 
the inclusion and exclusion criteria. They will then ask 
psychiatrists in each outpatient department if they are able 
to identify any patients who may be potentially eligible to 
take part in the study. The diagnosis of bipolar disorder will 
be made using DSM-5 criteria, following an unstructured 
interview led by the treating psychiatrist.
Researchers will work closely with the clinical team to 
determine whether patients are suitable to participate in the 
trial. If patients meet the inclusion criteria and the consultant 
psychiatrist and clinical team agree that they could be poten-
tial participants, the consultant will introduce the study to the 
patient. If the patient then agrees to be contacted by the research 
team, the research clinician will arrange an appointment to 
explain the study verbally and provide them with the participant 
information sheet. The patient will be given at least 24 hours to 
read and understand this leaflet. After this, if they decide that 
they are willing to take part, an appointment will be arranged 
to obtain signed informed consent for trial participation and 
also signed consent for access to their medical notes.
Screening
At the first visit, participants will undergo structured diag-
nostic interviews using the MINI to confirm a diagnosis 
of DSM-5 bipolar disorder and current major depressive 
episode.27 This tool has been validated for use in the Urdu 
language and has been used in previous studies in Pakistan.28 
The HAM-D-17 scale will be used to screen for depres-
sion (which must have been present for at least 4 weeks). 
A HAM-D-17 score $18 will be used as the minimum 
threshold for depression severity.29 Other inclusion/exclu-
sion criteria will be checked, consent will be confirmed and 
pregnancy testing (if appropriate) will be performed.
Follow-up
Participants will be randomized to take either:
1. Placebo-minocycline plus placebo-celecoxib
2. Active-minocycline plus placebo-celecoxib
3. Placebo-minocycline plus active-celecoxib
4. Active-minocycline plus active-celecoxib.
Participants will continue with the treatment currently 
provided by their clinical teams. Minocycline will be started 
at a dose of 100 mg daily and will be increased after 2 weeks 
to 200 mg daily, which will be taken as a single dose to 
encourage concordance. Celecoxib will be started at a dose of 
200 mg daily and will be increased after 2 weeks to 400 mg 
daily, which will be taken as a single dose to encourage 
concordance (Figure 1).
The clinical team and consultant psychiatrist will continue 
to oversee routine care for each participant although RAs 
will be contactable for the duration of the study to respond 
to any concerns. Contacts will be every 2 weeks until study 
completion (Table 2). A DMC will be constituted to supervise 
the trial data as they accrue. The DMC will draft a charter 
to ensure participant safety and will consider stopping the 
trial if there is an increased frequency of serious adverse 
events (eg, celecoxib-associated GI bleed or cardiovascular 
event and minocycline-associated lupus or serum sickness-
like reaction). 
???????? ?????? ?????? ?????? ???????
• ????????????????????????????????
• ??????????????????????????????
• ????????????????
• ???????????????????
• ????????????????????????????????
• ??????????????????????????????
• ???????????????????
• ???????????????????
• ???????????????
• ???????????????????
• ???????????????????
Figure 1 12-week assessment schedule.
Abbreviation: oD, once daily.
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outcome measures
The primary outcome measure will be mean change in HAM-D 
scale scores from baseline to week 12. For the purposes of this 
study, response is defined as a reduction of 50% or more of the 
HAM-D-17 score and remission is defined as a score of #7 of 
the HAM-D-17. The 24-item HAM-D scale will also be used to 
measure atypical depressive symptoms.30 Ratings will be made 
on the basis of a semi-structured clinical interview at baseline 
and at every biweekly follow-up visit until week 12.
Other outcomes recorded will include the CGI scale, an 
overall measure of illness severity, the PHQ-9,31 a measure 
of depression severity, and the GAD-7 questionnaire,32 a 
measure of severity for GAD. All scales have been validated 
for use in the Urdu language and have been used in previous 
studies in Pakistan.33 Adverse effects will be monitored using 
scales that have been specifically designed for minocycline 
and celecoxib. One of these rating scales has been used by 
the authors in a previous study.21
Measurement of biomarkers
Participants will be requested to provide two blood samples 
(at baseline and at week 12) for analysis. This is optional 
and does not influence recruitment to the study. Samples will 
be analyzed to investigate whether there is an association 
between minocycline/celecoxib and inflammatory markers 
and whether this relates to the participants’ experience of 
symptom change. The biomarkers analyzed will include 
complete blood count and CRP.
Inter-rater reliability
RAs have been trained in SCID and in carrying out clinical 
assessments by the University of Manchester for a previous 
grant-funded study. Inter-rater reliability will be measured 
throughout the study by local investigators. To establish 
inter-rater reliability, training videos will be used while two 
raters code them independently and will then be assessed 
with the intraclass correlation coefficient.
Statistical analysis
All analyses will be based on the ITT principle with all par-
ticipants included in the analysis as randomized. The primary 
outcome at week 12 (and other continuous measures) will be 
analyzed using linear regression models, adjusted for baseline 
outcome scores and including study center as fixed effect, 
with contrasts for minocycline versus non-minocycline and 
celecoxib versus non-celecoxib. Although the study is not 
powered to detect an interaction between the two treatment 
types, a regression model extended to include an interaction 
term will assess this. If an interaction is detected, the analy-
sis of minocycline and celecoxib alone versus placebo will 
be presented.34 Missing data will be assumed to be missing 
at random and accounted for with multiple imputation by 
chained equations (with 100 imputed datasets).35 To allow 
an unbiased estimate of treatment effect, baseline predictors 
of dropout will be sought and included in the imputation 
models. Model assumptions (homoscedasticity and normality 
of distributions) will be checked. Binary outcomes will be 
Table 2 overall study timeline indicating target milestones
Milestones (months) −3 1 3 4 5 6 8 12 16 18 22 24
Setting up/ethical approval
Staff recruitment/training
Patient recruitment
Intervention
Data entry
Write up and analysis
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analyzed using logistic regression and with equivalent design. 
If enough participants have provided biomarker samples, 
mediation models will assess potential association of treat-
ment effects on symptom outcomes by inflammatory markers. 
All analysis will be carried out in R 3.2 and Stata 14.1. 
Study coordination
Local investigators will chair a weekly meeting with RAs to 
help coordinate the study. The chief investigator will conduct 
meetings with the research team every 2 weeks via Skype.
Dissemination
Results will be reported in a peer review journal and will 
also be communicated at relevant national and international 
conferences. Study findings will also be shared through local 
newspapers for a general audience.
Discussion
Bipolar disorder is a prevalent condition that can have a pro-
found impact on an individual’s functioning. The depressive 
phase in both bipolar I and II subtypes remains a significant 
treatment challenge and current pharmacological strategies 
often have poor response, leaving patients with chronic 
residual symptoms. Recent studies indicate that the use of 
certain anti-inflammatory agents may lead to an improvement 
in depressive symptoms.
To our knowledge, there are currently no RCTs that 
have studied the use of minocycline in bipolar disorder. 
There is only one RCT investigating the use of celecoxib 
in bipolar depression, but this study had a small sample 
size. The factorial design RCT is the first study to look at 
both minocycline and celecoxib as adjunctive treatments 
for bipolar depression. The findings from this study may 
add to current evidence for the treatment of patients with 
bipolar disorder experiencing depressive symptoms. If this 
study indicates a trend that minocycline and/or celecoxib 
are beneficial in treating bipolar depressive symptoms, it 
will deliver immediate clinical benefit. Both compounds 
are inexpensive, off-patent drugs that are easily available 
worldwide. Both could potentially be a cost-effective 
treatment option in settings with diminishing resources 
such as low- and middle-income countries as well as other 
health care services including the NHS in the UK. In the 
long term, it is believed that the results of this trial will lead 
to increased treatment options for patients who experience 
bipolar depression, a condition that is often highly debilitat-
ing and challenging to treat.
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